Boehringer In­gel­heim preps FDA sub­mis­sion with new da­ta in rare pe­di­atric lung dis­ease

Ofev was one of Boehringer In­gel­heim’s top sell­ers in the first half of this year, rak­ing in a whop­ping $1.48 bil­lion. Now the Ger­man phar­ma gi­ant wants to ex­pand in­to the small group of pe­di­atric pa­tients with lung scar­ring dis­eases.

Boehringer In­gel­heim proved that a weight-based dos­ing reg­i­men of Ofev, al­so known as nintedanib, in kids be­tween 6 and 17 years old re­sult­ed in a dose ex­po­sure sim­i­lar to adults, ac­cord­ing to Phase III re­sults re­leased on Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.